anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
Waterpipe (WP) tobacco smoking (a.k.a. hookah, shisha, narghile) is increasing rapidly in the United States (US), particularly among young people. Evidence suggests that WP smoking can lead to dependence, other tobacco use, and many of the known smoking-related diseases including cancer, cardiovascular disease and adverse pregnancy outcomes. These alarming trends led the Food and Drug Administration (FDA) in 2014 to propose including the WP under its regulatory authority, allowing the FDA to apply evidence-based regulatory approaches to control WP spread in the US. Given the salience of flavored tobacco in shaping the "WP experience", regulating WP tobacco flavor represents a promising approach for the FDA to curb WP use among US youth. This project aims to assist the FDA in these efforts by providing answers to specific questions pertinent to the potential of WP regulation through flavor. These include: - How would flavor manipulation affect the smoking experience and satisfaction of WP users at different stages of their smoking trajectory - How would smoking non-preferred flavor or unflavored WP tobacco reflects on smokers' exposure to nicotine, and dependence; and - How would flavor manipulation influence puffing behavior and exposure to toxicants such as carbon monoxide (CO) among WP smokers. Answers to these questions will help the FDA predict the impact of flavor regulation on WP experimentation and continued use. In this study, investigators will use clinical laboratory methods to answer these questions. Two groups of WP smokers will be recruited based on their use frequency: low (Beginners) vs. high frequency (Experienced) smokers (72/group; total 144; age 18-30). Each participant will undergo 2 WP smoking sessions that differ by flavor (preferred flavor; unflavored), while measurement of WP satisfaction, dependence, harm perception, and exposure to nicotine and toxicants will be conducted. The response of WP smokers at different stages of their WP smoking trajectory (Beginners vs. Experienced) to flavor manipulation, will allow to predict the effect of limiting flavors on a wide range of WP smokers. This project promises to provide the first evidence to guide the FDA in terms of the potential of regulating WP flavored tobacco on WP uptake and use in the US.
Nutritional support is a crucial component of managing critically ill patients. The prognostic impact of early enteral nutrition (EN) in critically ill COVID-19 patients is largely unknown. The study aimed to determine the relationship between the nutritional profile of critically ill patients diagnosed with COVID-19 and disease severity, prognosis, and survival, to assess the ability to meet nutritional goals, EN complications, and reasons for discontinuation and postponement of feeding. Methods: This retrospective study was conducted with adult intensive care unit (ICU) patients diagnosed with COVID-19 and receiving mechanical ventilation (MV) and EN. The demographic, clinical, biochemical, and nutritional data of the patients were obtained from the patient's files and the hospital database. The initiation time, route, method, product type, amount, and duration of feeding were recorded, and the daily intake of energy, protein, pulp, and water were calculated. The nutritional requirements of the patients were defined, and achievement of targets, EN complications, and reasons for discontinuation and postponement were recorded. Patients were divided into two groups: early EN (EEN) if the feeding was initiated within the first 48 hours after MV and late EN (LEN) if 48 hours or later. The research outcomes are to determine the relationship between the duration of EN initiation and Prognostic Nutritional Index (PNI) score, neutrophil-lymphocyte ratio (NLR), oxygenation status, MV, ICU, and length of hospital stay, overall mortality, and whether nutritional goals were met, EN complications, and reasons for discontinuation and postponement.
AIMS: To assess the survival function of cementless total trapezium metacarpal prostheses (TTMPs) at 20 years, to compare survival functions by trapezium size, and to evaluate the association between the instantaneous risk of TTMP failure and small trapezium size using a multivariate Cox regression model.
METHODS: This observational cohort study included 221 consecutive patients with a mean follow-up after TTMP of 137.3 months (maximum of 246 months). Kaplan-Meier and actuarial life-table methods were used to evaluate the survival function of thecohort. Kaplan-Meier survival curves were compared by trapezium size. Multivariate Cox regression analysis was used to determine the effect of potential confounders on the association between small trapezium and the instantaneous risk of TTMP failure.
RESULTS: At the end of follow-up, there was a 89.01% chance of the TTMP surviving for 246 months or more. There was an association between TTMP survival time and trapezium size showing a significant trend such that the survival curves weresignificantly higher with larger trapezium size (Mantel-Cox test, p = 0.0001; WilcoxonBreslow test, p = 0.0002; Tarone-Ware test, p = 0.0001).The unadjusted Cox regression model showed a significant association between small trapezium size (smaller than 9 mm) and the instantaneous risk of TTPM failure (HR: 7.37, 95% CI: 2.46-22.07). In the multivariate Cox analysis, "age", "trapezium morphology", and "complications" were confounders in the association between small trapezium size and the hazard ratio of prosthetic failure (HR = 3.76; 95% CI 0.96 to 13.82).
CONCLUSION: These results confirm the long-term functional survival of TTMP prostheses and reveal a significant increase in trend of the survival curve with larger trapezium size. Patient age, trapezium morphology, and the presence of post-surgical complications are confounders in the association between small trapezium size and the hazard ratio of TTMP failure.
The proposed intervention consists of one hour of adapted physical activity per week for 12 weeks, led by a professional. In addition to this intervention, the intervention includes two 15-minute sessions, one before and one after the session. At the end of each session, a PA challenge and a positive reinforcement exercise will be proposed. The participants will have a week to try to achieve these. In addition to these two 15-minute sessions, participants will benefit from a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different topics related to diabetes.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of reducing skin irritation, which has been adverse side effects, low irritant, having high effects and useful for treating blows, etc., by formulating the composition indometacin and chlorpheniramine maleate therein. SOLUTION: This indomethacin-containing preparation composition for external use is obtained by formulating (A) 1 pt.wt. indomethacin with (B) 0.01-3.0 pts.wt. chlorpheniramine maleate. The amount of the formulated ingredient A is preferably 0.1-2.0wt.% and that of the formulated ingredient B is preferably 0.001-0.6wt.%. A lower alcohol, e.g. methanol, a dissolution auxiliary, e.g. diisopropyl adipate, a surfactant, etc., e.g. a sorbitan ester of a fatty acid may further be formulated.
OBJECTIVE: This study aims to assess how enhancing upper limb function on the affected side of stroke influences the gait of the lower limb.
METHODS: Forty eligible stroke patients were randomly assigned to either a control group or a treatment group, with 20 patients in each group. Both groups underwent dynamic evaluation using artificial intelligence and computer vision before treatment. This evaluation focused on analyzing the range of motion of the shoulder and elbow during the gait cycle, as well as various gait parameters (such as step length, step speed, and percentage of stance phase) on the affected side. Following evaluation, the control group received routine rehabilitation treatment.
RESULTS: The results indicated that there was no significant difference between the two groups before treatment. However, following treatment, there was a notable improvement in the motion of the shoulder and elbow joints on the affected side among patients in the treatment group (p<0.05), whereas the control group showed only slight improvement, which was not statistically significant (p>0.05).
CONCLUSION: The improvement in upper limb function on the affected side also appears to positively influence gait recovery. However, it's important to note that the observation period was relatively short. Further studies are needed to confirm whether this effect is sustained over the long term.
An apparatus for processing of medical images comprises a ( 101 ) receiver for receiving a an image representing characteristics of a part of a human or animal body. The image may for example be a magnetic resonance or computer tomography image. A signature unit ( 103 ) determines an image associated set of signatures from the first image. A sample store ( 109 ) comprises a data base in the form of a set of samples where each sample comprises a sample associated set of signatures and medical data. A matching unit ( 105 ) determines a set of matching samples from the set of samples in response to a comparison of the image associated set of signatures to the sample associated sets of signatures of the set of samples. A decision unit ( 111 ) then determines medical data for the image in response to the medical data comprised in the samples of the set of matching samples.
The subject's general health is assessed by a history and physical exam and routine blood work. I normal the individual undergoes five nights of receiving 1.5ug/kg of chloral hydrate. On day 6 the individual receives 2.5 micrograms/kg of Dichloroacetate (DCA) and kinetics are drawn. After 30 days the subject comes back and receives 1.5ug/kg of chloral hydrate for five nights and has kinetics drawn on night one and five. On days 6-9 the subject returns for a blood draw. After 30 days the same process as above is done except the subject receives 1gram of chloral hydrate for five nights and 25mg/kg of Dichloroacetate one day then 30 days later the subject receives 1gram of chloral hydrate for five nights and has kinetics done on night one and five and blood samples drawn on days 6-9
PURPOSE:To provide a carcinostatic assistant composed of extract of KAMI- SHOYOSAN or TOKAKU-SHOKITO which is a compounded Chinese herb drug for women's dizziness, having mitigated side effect of cisplatin such as renal disorder and useful as an assistant to promote effective and safe remedying effect of cisplatin. CONSTITUTION:The objective carcinostatic assistant for cisplatin is composed of an extract of KAMI-SHOYOSAN [composed of 3.0pts.(wt.) each of TOKI (root of Angelica acutiloba), SHAKUYAKU (root of Paeonia albiflora), BYAKUJUTSU (rhizome of Atractylodes japonica) and SAIKO (root of Bupleurum falcatum), 2.0pts. each of BOTANPI (root bark of Paeonia moutan) and SANSHISHI (fruit of Gardenia jasmioides), 1.5-2pts. of KANZO (root of Glycyrrhiza glabra var. glandulifera), 0.5-2pts. of SHOKYO (rhizome of Zingiber officinale) and 1.0pt. of HAKKA (leaf of Mentha arvensis)] or TOKAKU-SHOKITO [composed of 5pts. of TONIN (stone of Prunus persica), 4pts. of KEIHI (bark of Cinnamomum cassia), 1-3pts. of DAIO (rhizome of Rheum palmatum), 1pt. of dried sodium sulfate and 1.5pts. of KANZO]. The extract suppresses the increase of BUN value and creatinine value caused by cisplatin. It is preferably administered continuously even in the pausing period of the cisplatin administration.
OSA subjects will be recruited from the UCLA Sleep Disorders Center via recruitment flyers. When prospective subjects contact the study coordinator, the study will be explained in greater detail, and inclusion and exclusion criteria reviewed. If the person agrees to participate, appointments for data collection will be made and copies of the informed consent will be mailed for their review for at least 3 days before the study. Then the Project Coordinator or one of the PI's will contact the prospective subject, answer any questions about the study, and obtain signed, informed consent. Baseline measures (PSQI, BDI-II, height, weight, vital signs \[temperature, heart rate, blood pressure\]) will be obtained. At 6 weeks, baseline measures will be repeated and an overnight polysomnography study will be performed at the subject's home. All subjects will be given the WBV device at the end of the study. Delivery of the WBV device to each subject's home will be arranged and the WBV device and pedometer set up by the research team. Training in the use of the WBV device will be provided inperson and via written instructions. Phone and e-mail support for the WBV device or any study questions will be available for all study participants. Subjects will use the device at least 3 times/week, for 30 minutes per session, for 6 weeks. In addition to the pedometer, a wall calendar will be provided on which subjects will mark the days that they use the WBV device. Project Coordinator will visit subjects weekly, and as needed, to record pedometer readings, check wall calendar for WBV device use, and to answer any subjects' questions or concerns. Brain MRI scans will be performed at baseline and after 6 weeks. An MRI-compatible pulse oximeter, and an air-filled pressure transducer will be connected to the subject to monitor heart rate, O2 saturation, and thoracic wall movement, and then the subject will be positioned in the scanner for data collection.
Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
Ectopic varices are rare but potentially life-threatening conditions usually resulting from a combination of global portal hypertension and local occlusive components. As imaging, innovative devices, and interventional radiologic techniques evolve and are more widely adopted, interventional radiology is becoming essential in the management of ectopic varices. The interventional radiologist starts by diagnosing the underlying causes of portal hypertension and evaluating the afferent and efferent veins of ectopic varices with CT. If decompensated portal hypertension is causing ectopic varices, placement of a transjugular intrahepatic portosystemic shunt is considered the first-line treatment, although this treatment alone may not be effective in managing ectopic variceal bleeding because it may not sufficiently resolve focal mesenteric venous obstruction causing ectopic varices. Therefore, additional variceal embolization should be considered after placement of a transjugular intrahepatic portosystemic shunt. Retrograde transvenous obliteration can serve as a definitive treatment when the efferent vein connected to the systemic vein is accessible. Antegrade transvenous obliteration is a vital component of interventional radiologic management of ectopic varices because ectopic varices often exhibit complex anatomy and commonly lack catheterizable portosystemic shunts. Superficial veins of the portal venous system such as recanalized umbilical veins may provide safe access for antegrade transvenous obliteration. Given the absence of consensus and guidelines, a multidisciplinary team approach is essential for the individualized management of ectopic varices. Interventional radiologists must be knowledgeable about the anatomy and hemodynamic characteristics of ectopic varices based on CT images and be prepared to consider appropriate options for each specific situation. ©RSNA, 2024 Supplemental material is available for this article.
BACKGROUND: Stemless shoulder arthroplasty offers several advantages, such as preserving bone stock and reducing periprosthetic fracture risk. However, implant motion can deter osteointegration and increase bone resorption, where micromotion less than 0.150 mm is crucial for bony ingrowth and vital to the success of the implant. The interaction between the implant and the metaphyseal bone and its effects on stability remains unclear. Therefore, this cadaveric study aims to assess the immediate stability of two stemless prostheses in low bone density specimens.
METHODS: Twenty cadaveric shoulders were used to compare the stability of two stemless shoulder implants by Zimmer-Biomet (model A) and Exactech (model B), subjected to loads of 220 N, 520 N, and 820 N to assess strain and micromotion.
FINDINGS: Micromotion at 220 N load was 0.061 ± 0.080 mm and 0.053 ± 0.050 mm, and at 520 N load, 0.279 ± 0.37 mm and 0.311 ± 0.35 mm for models A and B, respectively. The estimated mean force required to achieve a 150 μm micromotion was 356 ± 116 N and 315 ± 61 N for models A and B, respectively. Motion analysis revealed distinct movement patterns for each implant, with model B demonstrating better force distribution on the bone despite no significance.
INTERPRETATION: Forces over 520 N (high postoperative rehabilitation force) could hinder bone integration with prostheses due to excessive micromotion. Conversely, forces around 220 N (preconditioning loading force) are considered safe for prosthesis stability even with low bone density. These insights may caution against using stemless implants when bone density is low, and help guide clinical decisions on the duration of rehabilitation and sling use after stemless arthroplasty.
Neuropathic pain is a debilitating disease with poor treatment options. Clinical investigations conclude that early therapeutic intervention is crucial for increasing the therapeutic success and for ameliorating neuropathic pain. However, in patients with diabetes or patients that suffer from adverse events of chemotherapy, the onset of neuropathic pain is difficult to estimate. For this reason, biomarkers represent important diagnostic markers that may be used for therapeutic strategies and, in an ideal case, for the prediction of onset, intensity and duration of neuropathic pain even before the first symptoms arise in patients. 
     Using animal models of neuropathic pain, we observe that oxidized lipids and epoxylipids are generated in nervous tissue and plasma even before neuropathic pain arises in the animals. We therefore suggest determination of the concentrations of these lipids by mass spectrometry (LC-MS/MS) in the plasma of patients as potential biomarkers for neuropathic pain. Using this method, high-risk patients may be identified early and pharmacological treatment may start before neuropathic pain is established. The early treatment may lead to a reduction or even prevention of neuropathic pain in these patients.
Hepatorenal syndrome, severe acute renal failure including fatal cases, and renal insufficiency can occur with erlotinib treatment. Renal failure may arise from exacerbation of underlying baseline hepatic impairment or severe dehydration. The pooled incidence of severe renal impairment in the 3 monotherapy lung cancer studies was 0.5% in the erlotinib arms and 0.8% in the control arms. The incidence of renal impairment in the pancreatic cancer study was 1.4% in the erlotinib plus gemcitabine arm and 0.4% in the control arm. Withhold erlotinib in patients developing severe renal impairment until renal toxicity is resolved. Perform periodic monitoring of renal function and serum electrolytes during erlotinib treatment [see Adverse Reactions (6.1) and Dosage and Administration (2.4)]
FIELD: veterinary science, biotechnology. SUBSTANCE: vaccine contains aluminium hydroxide-adsorbed formalin-inactivated leucocidine- exotoxin, suspension of alive spores of anthracic vaccine strain 55-VNIIVV&M at initial concentration being (5-5,5)•10 9  spores/cm 3  in physiological solution, 1 M-sodium metabisulfite solution and an oily adjuvant. Vaccine components are in a balanced ratio. Leucocidine-exotoxin is a highly purified protein at 18-20 kDa molecular weight. It is obtained out of production strain Fusobacterium necrophorum "0-1" VIEV. Associated vaccine is once injected for cattle, sheep, goats, pigs and Siberian stags intracutaneously with the help of a needle-free injector at 0.2-0.4 cm 3  volume. Associated vaccine against anthrax and necrobacteriosis is a highly efficient preparation to protect animals against these diseases, according to its immunogenicity it surpasses monovaccines that it contains. EFFECT: higher efficiency of prophylaxis. 2 ex
PROBLEM TO BE SOLVED: To discriminate automatically eyeground photographs from a variety of angles by discriminating the top or bottom, a specified angle or the surface or reverse of an eyeground photograph read with a photographic image reader. SOLUTION: An image of a slide original image 203 photographed with a lighting device 202 is imaged with a lens 204 and a video camera 205, and stored temporarily in a frame memory 206. Here the surface or the reverse of the slide is determined. The video camera 205 and the frame memory 206 make up a photographic image reader. Determination of the top or bottom, or 90 deg. rotation or the surface or the reverse is executed with a central processor 212 to an image on the frame memory 206. Just before image display, a visual field restrictor 21 is provided and regulates the shape of the visual field on the image display face. The visual field restrictor 21 has a circular opening 100, and a notch 101 in a part thereof. An examiner can automatically determine the surface or the reverse of an image by the direction of the notch 101.
A multicenter clinical study of carralizumab combined with albumin paclitaxel and apatinib mesylate in the second-line treatment of advanced or metastatic cholangiocarcinoma.Albumin-bound paclitaxel 125 mg/m2 d1,8; Carrilizumab 200mg Q3W d1; Apatinib mesylate tablet treatment: 250mg orally, once a day, continuous administration. Treatment continued or was evaluated every 2 cycles until disease progression or toxic side effects of patient intolerance to the treatment regimen.
A computing system for determining osteogenic loading from an exercise apparatus for performing an exercise is provided. The exercise apparatus includes a loading interface, a frame, a linear adjustment system interposing between and fixedly coupled to the loading interface and the frame, and a sensor coupled to the linear adjustment system. A position of the loading interface of the exercise apparatus is adjusted through a movement of the linear adjustment system at one or more intermediate positions of a plurality of functional positions of the loading interface. A force exerted by a subject on the loading interface at the position in the one or more intermediate positions is received. A measurement of the force exerted by the subject on the loading interface at the position in the one or more intermediate positions from the sensor is obtained. A corresponding osteogenic loading for the force exerted by the subject is determined.